Athenex (NASDAQ:ATNX)'s stock had its "hold" rating reissued by Truist Securities in a research note issued on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock, down from their previous price target of $29.00. Truist Securities' target price would indicate a potential upside of 30.72% from the stock's previous close.
A number of other equities analysts have also weighed in on ATNX. Royal Bank of Canada upped their target price on Athenex from $9.00 to $33.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 2nd. Laidlaw reduced their price objective on shares of Athenex from $38.00 to $13.00 and set a "buy" rating for the company in a research report on Monday, March 1st. Zacks Investment Research cut Athenex from a "buy" rating to a "hold" rating in a research note on Wednesday, February 17th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $7.00 target price (down from $30.00) on shares of Athenex in a research note on Monday. Finally, Evercore ISI began coverage on shares of Athenex in a research note on Wednesday, February 10th. They set an "outperform" rating on the stock. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. The company presently has a consensus rating of "Hold" and an average target price of $14.67.
Shares of ATNX stock traded up $0.09 on Tuesday, hitting $4.59. 65,080 shares of the company's stock were exchanged, compared to its average volume of 2,941,402. Athenex has a 12 month low of $3.93 and a 12 month high of $15.24. The company has a debt-to-equity ratio of 0.57, a current ratio of 4.87 and a quick ratio of 4.43. The company has a 50 day moving average of $11.70 and a 200 day moving average of $12.05. The stock has a market cap of $428.96 million, a P/E ratio of -3.13 and a beta of 0.92.
Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Sunday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Athenex had a negative return on equity of 66.12% and a negative net margin of 75.45%. Sell-side analysts predict that Athenex will post -1.5 EPS for the current fiscal year.
In related news, insider William Wei Zuo sold 419,931 shares of the stock in a transaction dated Thursday, March 4th. The shares were sold at an average price of $4.52, for a total value of $1,898,088.12. Following the completion of the transaction, the insider now directly owns 142,883 shares in the company, valued at approximately $645,831.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 16.30% of the company's stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC grew its stake in shares of Athenex by 17.3% in the 3rd quarter. Perceptive Advisors LLC now owns 13,532,467 shares of the company's stock worth $161,323,000 after buying an additional 2,000,000 shares during the last quarter. BlackRock Inc. boosted its holdings in Athenex by 17.6% in the fourth quarter. BlackRock Inc. now owns 6,120,240 shares of the company's stock worth $67,690,000 after acquiring an additional 915,103 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new position in shares of Athenex during the third quarter valued at $13,915,000. Schonfeld Strategic Advisors LLC boosted its stake in Athenex by 345.2% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 873,656 shares of the company's stock worth $10,571,000 after purchasing an additional 677,422 shares in the last quarter. Finally, Northern Trust Corp grew its position in Athenex by 10.9% during the 4th quarter. Northern Trust Corp now owns 814,757 shares of the company's stock valued at $9,012,000 after purchasing an additional 80,394 shares during the last quarter. 57.74% of the stock is currently owned by hedge funds and other institutional investors.
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Read More: How are capital gains distributions different for tax-deferred account?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Quiet Period Expirations7 Things You Need To Know About Cryptocurrency
The Cryptocurrency Market Is About To Boil Over
The cryptocurrency was quiet for years, but it’s starting to boil over once again. With the price of Bitcoin up 550%, it certainly seems like the sky is the limit.
Whether or not you choose to trade Bitcoin or any other cryptocurrency, it is important to understand what it is and the trends driving it.
The bottom line, however, is that the world’s money is flowing onto the blockchain, and the use of cryptocurrency is growing at an exponential rate.
View the "7 Things You Need To Know About Cryptocurrency"